News

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

- Near doubling of 1-year overall survival (OS), increased median OS of 4 months (12.5 vs 8.5 months), and 43% reduction in risk of death in patients treated with at least one cycle (4 weeks) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) vs GnP alone

06/24/2025

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusib Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusib

06/20/2025

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Actuate Therapeutics Inc (ACTU) a buy, sell, or hold?

Actuate Therapeutics Inc (ACTU) can sell. Click on Rating Page for detail.

What is Actuate Therapeutics Inc's stock price?

The price of Actuate Therapeutics Inc (ACTU) is 6.75 and it was updated on 2025-07-02 13:00:19.

Is Actuate Therapeutics Inc (ACTU) overvalued or undervalued?

Currently Actuate Therapeutics Inc (ACTU) is in undervalued.

News

From:

To:

News
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes CHICAGO and FORT WORTH, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced today that the Company will be added to the Russell 3000® Index, with automatic inclusion in the Russell 2000® Index, effective after the U.S. market close on June 27, as part of the 2025 Russell indexes annual reconstitution. The inclusion follows the initial announcement on Friday, May 23, and the latest update on Friday, June 13, 2025, in connection with the annual reconstitution of the Russell U.S. Indexes. Mon, Jun. 16, 2025
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer CHICAGO and FORT WORTH, Texas, May 31, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today presented topline results from the Phase 2 (Actuate-1801 Part 3B) trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) at the American Society of Clinical Oncology (ASCO) Annual Meeting. Sat, May. 31, 2025
Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer CHICAGO and FORT WORTH, Texas, May 22, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the online publication of the abstract accepted as an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 30-June 3, in Chicago, Illinois. Thu, May. 22, 2025
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - Oral presentation at ASCO to highlight topline Phase 2 data of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) Wed, Apr. 23, 2025
Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025 CHICAGO and FORT WORTH, Texas, April 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that data on elraglusib in advanced salivary gland carcinoma will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place from April 25th – 30th at McCormick Place Convention Center, Chicago, IL. The abstracts will be published in the online Proceedings of the AACR. Thu, Apr. 17, 2025

SEC Filings

SEC Filings
Actuate Therapeutics Inc (ACTU) - SCHEDULE 13D/A SEC Filings 06/30/2025
Actuate Therapeutics Inc (ACTU) - 4 SEC Filings 06/30/2025
Actuate Therapeutics Inc (ACTU) - 8-K - Current report SEC Filings 06/26/2025
Actuate Therapeutics Inc (ACTU) - 8-K - Current report SEC Filings 06/05/2025
Actuate Therapeutics Inc (ACTU) - 8-K - Current report SEC Filings 06/02/2025
Actuate Therapeutics Inc (ACTU) - SCHEDULE 13D/A SEC Filings 05/27/2025
Actuate Therapeutics Inc (ACTU) - 8-K - Current report SEC Filings 05/23/2025
Actuate Therapeutics Inc (ACTU) - 4 SEC Filings 05/23/2025
Actuate Therapeutics Inc (ACTU) - S-8 SEC Filings 05/15/2025
Actuate Therapeutics Inc (ACTU) - 10-Q - Quarterly Report SEC Filings 05/15/2025
Actuate Therapeutics Inc (ACTU) - 8-K - Current report SEC Filings 05/06/2025
Actuate Therapeutics Inc (ACTU) - EFFECT SEC Filings 04/17/2025
Actuate Therapeutics Inc (ACTU) - 424B3 SEC Filings 04/16/2025
Actuate Therapeutics Inc (ACTU) - D SEC Filings 04/10/2025
Actuate Therapeutics Inc (ACTU) - DEFA14A SEC Filings 04/09/2025
Actuate Therapeutics Inc (ACTU) - DEF 14A SEC Filings 04/08/2025
Actuate Therapeutics Inc (ACTU) - 4 SEC Filings 04/02/2025
Actuate Therapeutics Inc (ACTU) - S-1 SEC Filings 03/28/2025
Actuate Therapeutics Inc (ACTU) - 8-K - Current report SEC Filings 03/28/2025
Actuate Therapeutics Inc (ACTU) - 10-K - Current report SEC Filings 03/13/2025
Actuate Therapeutics Inc (ACTU) - 8-K - Current report SEC Filings 02/07/2025
Actuate Therapeutics Inc (ACTU) - 8-K - Current report SEC Filings 12/17/2024
Actuate Therapeutics Inc (ACTU) - 10-Q - Quarterly Report SEC Filings 11/13/2024
Actuate Therapeutics Inc (ACTU) - 8-K - Current report SEC Filings 11/12/2024
Actuate Therapeutics Inc (ACTU) - 10-Q - Quarterly Report SEC Filings 09/24/2024
Actuate Therapeutics Inc (ACTU) - 4/A SEC Filings 08/20/2024
Actuate Therapeutics Inc (ACTU) - SC 13D SEC Filings 08/19/2024
Actuate Therapeutics Inc (ACTU) - 8-K - Current report SEC Filings 08/19/2024
Actuate Therapeutics Inc (ACTU) - 4 SEC Filings 08/16/2024
Actuate Therapeutics Inc (ACTU) - S-8 SEC Filings 08/14/2024
Actuate Therapeutics Inc (ACTU) - 8-K - Current report SEC Filings 08/14/2024
Actuate Therapeutics Inc (ACTU) - 4 SEC Filings 08/14/2024
Actuate Therapeutics Inc (ACTU) - 3 SEC Filings 08/14/2024
Actuate Therapeutics Inc (ACTU) - EFFECT SEC Filings 08/13/2024
Actuate Therapeutics Inc (ACTU) - SEC STAFF LETTER SEC Filings 08/13/2024
Actuate Therapeutics Inc (ACTU) - POS EX SEC Filings 08/13/2024
Actuate Therapeutics Inc (ACTU) - 424B4 SEC Filings 08/13/2024
Actuate Therapeutics Inc (ACTU) - CORRESP SEC Filings 08/12/2024
Actuate Therapeutics Inc (ACTU) - CERT SEC Filings 08/12/2024
Actuate Therapeutics Inc (ACTU) - 8-A12B/A SEC Filings 08/12/2024
Actuate Therapeutics Inc (ACTU) - 3 SEC Filings 08/12/2024
Actuate Therapeutics Inc (ACTU) - CORRESP SEC Filings 08/02/2024
Actuate Therapeutics Inc (ACTU) - CORRESP SEC Filings 07/30/2024
Actuate Therapeutics Inc (ACTU) - CORRESP SEC Filings 07/26/2024
Actuate Therapeutics Inc (ACTU) - S-1/A SEC Filings 07/23/2024
Actuate Therapeutics Inc (ACTU) - FWP SEC Filings 07/23/2024
Actuate Therapeutics Inc (ACTU) - S-1/A SEC Filings 07/19/2024
Actuate Therapeutics Inc (ACTU) - FWP SEC Filings 07/19/2024
Actuate Therapeutics Inc (ACTU) - CORRESP SEC Filings 07/19/2024
Actuate Therapeutics Inc (ACTU) - CORRESP SEC Filings 07/17/2024
Actuate Therapeutics Inc (ACTU) - S-1/A SEC Filings 07/16/2024
Actuate Therapeutics Inc (ACTU) - CORRESP SEC Filings 07/15/2024
Actuate Therapeutics Inc (ACTU) - S-1/A SEC Filings 06/21/2024
Actuate Therapeutics Inc (ACTU) - FWP SEC Filings 06/21/2024
Actuate Therapeutics Inc (ACTU) - CORRESP SEC Filings 06/21/2024
Actuate Therapeutics Inc (ACTU) - 8-A12B SEC Filings 06/20/2024
Actuate Therapeutics Inc (ACTU) - UPLOAD SEC Filings 06/18/2024
Actuate Therapeutics Inc (ACTU) - S-1/A SEC Filings 06/11/2024
Actuate Therapeutics Inc (ACTU) - FWP SEC Filings 06/11/2024
Actuate Therapeutics Inc (ACTU) - CORRESP SEC Filings 06/11/2024
Actuate Therapeutics Inc (ACTU) - UPLOAD SEC Filings 05/31/2024
Actuate Therapeutics Inc (ACTU) - S-1 SEC Filings 05/24/2024
Actuate Therapeutics Inc (ACTU) - CORRESP SEC Filings 05/24/2024
Actuate Therapeutics Inc (ACTU) - UPLOAD SEC Filings 05/20/2024
Actuate Therapeutics Inc (ACTU) - DRS/A SEC Filings 05/13/2024
Actuate Therapeutics Inc (ACTU) - DRSLTR SEC Filings 05/10/2024
Actuate Therapeutics Inc (ACTU) - UPLOAD SEC Filings 05/08/2024
Actuate Therapeutics Inc (ACTU) - DRSLTR SEC Filings 04/30/2024
Actuate Therapeutics Inc (ACTU) - DRS/A SEC Filings 04/30/2024
Actuate Therapeutics Inc (ACTU) - UPLOAD SEC Filings 04/19/2024
Actuate Therapeutics Inc (ACTU) - DRSLTR SEC Filings 04/09/2024
Actuate Therapeutics Inc (ACTU) - DRS/A SEC Filings 04/09/2024
Actuate Therapeutics Inc (ACTU) - SEC STAFF LETTER SEC Filings 04/03/2024
Actuate Therapeutics Inc (ACTU) - UPLOAD SEC Filings 04/01/2024
Actuate Therapeutics Inc (ACTU) - D SEC Filings 03/06/2024
Actuate Therapeutics Inc (ACTU) - DRSLTR SEC Filings 03/04/2024
Actuate Therapeutics Inc (ACTU) - DRS SEC Filings 03/04/2024
Actuate Therapeutics Inc (ACTU) - D/A SEC Filings 12/15/2022
Actuate Therapeutics Inc (ACTU) - D SEC Filings 10/19/2022
Actuate Therapeutics Inc (ACTU) - D SEC Filings 12/10/2020
Actuate Therapeutics Inc (ACTU) - D/A SEC Filings 11/14/2019
Actuate Therapeutics Inc (ACTU) - D SEC Filings 10/15/2019
Actuate Therapeutics Inc (ACTU) - D SEC Filings 05/13/2019
Actuate Therapeutics Inc (ACTU) - D SEC Filings 09/12/2018
Actuate Therapeutics Inc (ACTU) - D SEC Filings 03/20/2017
Actuate Therapeutics Inc (ACTU) - D SEC Filings 02/03/2017
Actuate Therapeutics Inc (ACTU) - D SEC Filings 10/08/2015

Press Releases

StockPrice Release
Actuate therapeutics highlights significant and sustained survival benefit in key metastatic pancreatic cancer patient populations in phase 2 elraglusib trial 06/24/2025
Actuate therapeutics reports positive biomarker and machine learning data from phase 2 elraglusib trial in first-line treatment of metastatic pancreatic cancer at asco 06/20/2025
Actuate therapeutics announces inclusion in the russell 3000® and russell 2000® indexes 06/16/2025
Actuate therapeutics presents topline elraglusib phase 2 data at asco 2025 annual meeting: trial meets primary endpoint of median overall survival and doubles 1-year survival in first-line treatment of metastatic pancreatic cancer 05/31/2025
Actuate therapeutics announces details for 2025 asco annual meeting presentation on topline elraglusib phase 2 data in first-line treatment of metastatic pancreatic cancer 05/22/2025
Actuate to present elraglusib phase 2 topline data at the 2025 american society of clinical oncology (asco) annual meeting 04/23/2025
Actuate to present promising data on elraglusib in advanced salivary gland carcinoma at the aacr annual meeting 2025 04/17/2025
Actuate therapeutics to participate in upcoming investor conferences in february 02/06/2025
Actuate therapeutics announces positive interim phase 2 data of elraglusib in first line treatment of metastatic pancreatic cancer 12/17/2024
Actuate to participate in lantern's pharma webinar on ai-driven drug development 10/29/2024
Actuate therapeutics obtains complete responses and provides update on clinical trial of elraglusib for the treatment of relapsed/refractory ewing sarcoma 09/09/2024
Actuate to present at the h.c. wainwright 26th annual global investment conference 09/05/2024
Actuate therapeutics announces closing of initial public offering 08/14/2024
Actuate therapeutics announces pricing of initial public offering 08/12/2024

More Headlines

News
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February CHICAGO and FORT WORTH, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that Daniel Schmitt, President & Chief Executive Officer of Actuate will participate in the following upcoming investor conferences: 02/06/2025
Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer CHICAGO and FORT WORTH, Texas, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced new positive data from its ongoing and fully enrolled randomized Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (Actuate-1801 Part 3B). 12/17/2024
Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced that it will participate in “ Webinar Wednesday ” hosted by Lantern Pharma on October 30, 2024. 10/29/2024
Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma CHICAGO and FORT WORTH, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- – Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), provided an update on its Phase 1/2 trial of elraglusib in relapsed/refractory Ewing Sarcoma (r/r EWS). 09/09/2024
Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference CHICAGO and FORT WORTH, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, including pancreatic cancer and Ewing sarcoma, through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced that it will present at the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City. In addition, the management team will be available for one-on-one meetings during the conference. 09/05/2024
U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline This week was another slow week for pricings, with two companies making their public debut, along with three SPACs. On the filing side, offshore-focused drilling equipment and aftermarket service provider, HMH Holding, filed to raise $100 million. Three IPOs are currently scheduled to list in the week ahead, all based in the Asia Pacific region. One SPAC is also expected to price. 08/17/2024
Actuate Therapeutics Announces Closing of Initial Public Offering CHICAGO and FORT WORTH, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, announced today the closing of its previously announced initial public offering of 2,800,000 shares of its common stock, at a price of $8.00 per share to the public for a total of $22,400,000 of gross proceeds to the Company, before deducting underwriting discounts and offering expenses (the “Offering”). In addition, the Company has granted a 30-day option to the underwriters to purchase up to 420,000 additional shares, representing 15% of the shares sold in the Offering, solely to cover over-allotments, if any, at the initial public offering price, less the underwriting discounts and commissions. All of the shares are being offered by the Company. The shares began trading on August 13, 2024 on the Nasdaq Global Market under the symbol “ACTU.” 08/14/2024
Actuate Therapeutics Announces Pricing of Initial Public Offering CHICAGO and FORT WORTH, Texas, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (Nasdaq: ACTU) (the “Company”), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, announced today the pricing of its initial public offering of 2,800,000 shares of its common stock, at a price of $8.00 per share to the public for a total of $22,400,000 of gross proceeds to the Company, before deducting underwriting discounts and offering expenses (the “Offering”). 08/12/2024
U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing 08/03/2024
U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week A handful of IPOs priced this past week, led by three sizable names. One large issuer joined both the pipeline and the calendar - Chile-based LATAM Airlines Group. Six IPOs are scheduled to list in the week ahead and are set to raise a combined $5.1 billion, the most for any week so far this year. One SPAC is also set to debut. 07/20/2024
Actuate Therapeutics Seeks IPO For Promising Pancreatic Cancer Drugs Actuate Therapeutics, Inc. has filed for a $50 million IPO to raise funds for its treatments for pancreatic cancer and other cancer conditions. The global market for pancreatic cancer treatment is forecasted to reach $4.2 billion by 2025, driving the potential growth for Actuate Therapeutics. The company's lead program, elraglusib, has shown promising initial efficacy results in Phase 2 trials. 05/28/2024

Unlock

ACTU Ratings Summary

ACTU Quant Ranking

Is Actuate Therapeutics Inc (ACTU) a buy, sell, or hold?

What is Actuate Therapeutics Inc's stock price?

Is Actuate Therapeutics Inc (ACTU) overvalued or undervalued?

Actuate Therapeutics to Participate in Upcoming Investor Conferences in February

Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer

Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference

U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline

Actuate Therapeutics Announces Closing of Initial Public Offering

Actuate Therapeutics Announces Pricing of Initial Public Offering

U.S. IPO Weekly Recap: August Kicks Off With One Small Pricing

U.S. IPO Weekly Recap: Insurance And Healthcare Lead A 4 IPO Week

Actuate Therapeutics Seeks IPO For Promising Pancreatic Cancer Drugs

Company Details

Ratings

Quant Factor Grades

Trading

Dividend Grades

Dividend

Earnings

Valuation

Growth